Optas, LLC Biogen Inc. Transaction History

Optas, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 26, 2022	SELL	$223.92 - $287.77 $179,359 - $230,503	-801 Closed	0 $0
Q3 2021 Oct 14, 2021	BUY	$282.99 - $369.05 $1,131 - $1,476	4 Added 0.5%	801 $226,000
Q2 2021 Jul 27, 2021	BUY	$259.0 - $414.71 $259 - $414	1 Added 0.13%	797 $277,000
Q1 2021 Apr 19, 2021	BUY	$242.95 - $284.63 $193,388 - $226,565	796 New	796 $223,000
Q4 2020 Jan 27, 2021	SELL	$236.26 - $355.63 $243,111 - $365,943	-1,029 Closed	0 $0
Q3 2020 Oct 23, 2020	BUY	$264.77 - $305.71 $24,623 - $28,431	93 Added 9.94%	1,029 $293,000
Q2 2020 Jul 31, 2020	SELL	$258.66 - $342.55 $201,237 - $266,503	-778 Reduced 45.39%	936 $250,000
Q1 2020 Apr 14, 2020	SELL	$268.85 - $341.04 $10,485 - $13,300	-39 Reduced 2.22%	1,714 $542,000
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $385,765 - $533,034	1,753 New	1,753 $521,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Optas, LLC, based on Form 13F filings with the SEC.

Stay updated on Optas, LLC with notifications on news.